177 related articles for article (PubMed ID: 30057378)
1. Serum chemokine CXCL8 as a better biomarker for diagnosis and prediction of pancreatic cancer than its specific receptor CXCR2, C-reactive protein, and classic tumor markers CA 19-9 and CEA.
Litman-Zawadzka A; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
Pol Arch Intern Med; 2018 Sep; 128(9):524-531. PubMed ID: 30057378
[TBL] [Abstract][Full Text] [Related]
2. Specific Receptors for the Chemokines CXCR2 and CXCR4 in Pancreatic Cancer.
Litman-Zawadzka A; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Kędra B; Mroczko B
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867211
[TBL] [Abstract][Full Text] [Related]
3. Serum concentrations of receptor for interleukin 8 in patients with esophageal cancer.
Łukaszewicz-Zając M; Kulczyńska-Przybik A; Muszyński P; Kozłowski M; Szmitkowski M; Mroczko B
Pol Arch Med Wewn; 2016 Oct; 126(11):854-861. PubMed ID: 27906878
[TBL] [Abstract][Full Text] [Related]
4. Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer.
Lukaszewicz-Zając M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
Clin Exp Med; 2011 Jun; 11(2):89-96. PubMed ID: 20938721
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis.
Mroczko B; Groblewska M; Gryko M; Kedra B; Szmitkowski M
J Clin Lab Anal; 2010; 24(4):256-61. PubMed ID: 20626020
[TBL] [Abstract][Full Text] [Related]
6. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Utility of Serum CXCR-2 Assessment in Colorectal Cancer (CRC) Patients.
Pączek S; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
Anticancer Res; 2021 Mar; 41(3):1421-1428. PubMed ID: 33788733
[TBL] [Abstract][Full Text] [Related]
9. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
10. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
11. The Feasibility of Serum Multiple Tumor Markers Test Between Patients with Primary Pancreatic Cancer and Those with Benign Pancreatic Cystic Disease.
Lee JH
Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625360
[TBL] [Abstract][Full Text] [Related]
12. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
13. Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients.
Łukaszewicz-Zając M; Mroczko B; Kozłowski M; Nikliński J; Laudański J; Szmitkowski M
Dis Esophagus; 2012 Apr; 25(3):242-9. PubMed ID: 21895853
[TBL] [Abstract][Full Text] [Related]
14. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
15. CXCL-8 in Preoperative Colorectal Cancer Patients: Significance for Diagnosis and Cancer Progression.
Pączek S; Łukaszewicz-Zając M; Gryko M; Mroczko P; Kulczyńska-Przybik A; Mroczko B
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192002
[No Abstract] [Full Text] [Related]
16. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma.
Zhang SY; Lin M; Zhang HB
Int J Clin Exp Pathol; 2015; 8(8):9404-9. PubMed ID: 26464695
[TBL] [Abstract][Full Text] [Related]
18. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
19. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]